<DOC>
	<DOCNO>NCT00428350</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy quetiapine fumarate ( Seroquel ) daily dose 600mg-750mg used mono-therapy treatment acute schizophrenic patient evaluation change baseline PANSS total score Day 56 use last observation carry forward ( LOCF ) method .</brief_summary>
	<brief_title>Study Efficacy Safety Seroquel ( Quetiapine Fumarate ) Mono-Therapy Acute Schizophrenic</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent study participation initiation study related procedure , sign patient 's legal guardian Female and/or male , age 18 60 year ( inclusive ) Is hospitalise psychiatric unit acute episode schizophrenia define CCMD3 criterion one following : [ 20.1 ] paranoid schizophrenia , [ 20.2 ] hebephrenic schizophrenia , [ 20.3 ] catatonic schizophrenia , [ 20.5 ] undifferentiated schizophrenia CCMD3 diagnosis mental retardation Psychosis judge direct physiological effect abuse medication substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>